Merck MRK and Pfizer PFE are leading pharmaceutical companies with strong product and pipeline portfolios in oncology. Both companies also have presences in vaccines, neuroscience, and immunology ...

Pfizer has, however, faced its share of pipeline setbacks. Among more recent setbacks, in April 2025, Pfizer announced that it is discontinuing the development of its GLP-1R agonist, danuglipron ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See why I rate PFE stock a Buy.

** Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV® and KEYTRUDA® in patients with previously untreated metastatic urothelial cancer.

Padcev from Pfizer and Astellas Pharma is approved with Merck's Keytruda as a first-line bladder cancer therapy, and booked $1.69 billion in sales last year.

So yes, it may be disappointing to see Pfizer's revenue on the decline today, and at a level of about $13 billion in the recent quarter. But the company is at a key transition point, and it's ...

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more.

Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.